Contact
Please use this form to send email to PR contact of this press release:
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
TO:
Please use this form to send email to PR contact of this press release:
Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
TO: